Find a Research Lab

Research Lab Results

Results per page:

  • Katherine Wilson Lab

    Research in the Wilson Lab focuses on three components of nuclear lamina structure: lamins, LEM-domain proteins (emerin), and BAF. These three proteins all bind each other directly, and are collectively required to organize and regulate chromatin, efficiently segregate chromosomes and rebuild nuclear structure after mitosis. Mutations in one or more of these proteins cause a variety of diseases including Emery-Dreifuss muscular dystrophy (EDMD), cardiomyopathy, lipodystrophy and diabetes, and accelerated aging. We are examining emerin's role in mechanotransduction, how emerin and lamin A are regulated, and whether misregulation contributes to disease.
  • Fu Lab

    The Fu Lab is a basic research lab that studies zinc transport, with a particular focus on which step in the zinc transport process may be modulated and how. Dr. Fu's lab uses parallel cell biology and proteomic approaches to understand how these physiochemical principles are applied to mammalian zinc transporters and integrated to the physiology of pancreatic beta cells. This research has implications for understanding how zinc transport is related to diabetes and insulin intake.
    Lab Website

    Principal Investigator

    Dax Fu, PhD

    Department

    Physiology

  • Michael Wolfgang Laboratory

    The Wolfgang Laboratory is interested in understanding the metabolic properties of neurons and glia at a mechanistic level in situ. Some of the most interesting, enigmatic and understudied cells in metabolic biochemistry are those of the nervous system. Defects in these pathways can lead to devastating neurological disease. Conversely, altering the metabolic properties of the nervous system can have surprisingly beneficial effects on the progression of some diseases. However, the mechanisms of these interactions are largely unknown. We use biochemical and molecular genetic techniques to study the molecular mechanisms that the nervous system uses to sense and respond to metabolic cues. We seek to understand the neurometabolic regulation of behavior and physiology in obesity, diabetes and neurological disease. Current areas of study include deconstructing neurometabolic pathways to understand the biochemistry of the nervous system and how these metabolic pathways impact animal behavior and physiology, metabolic heterogeneity and the evolution of metabolic adaptation.

    Principal Investigator

    Michael J. Wolfgang, PhD

    Department

    Biological Chemistry

  • Mihail Zilbermint Lab

    Research in the Mihail Zilbermint Lab focuses on diabetes, adrenal disease and thyroid disease. Recent areas of focus include pseudohypoaldosteronism type 1 related to novel variants of SCNN1B gene, genetic variance in the ARMC5 gene in primary macronodular adrenocortical hyperplasia and hyperaldosteronism due to de novo KCNJ5 mutation.

    Principal Investigator

    Mihail Zilbermint, MD MBA

    Department

    Medicine

  • Michael Matunis Lab

    Research in the Michael Matunis Lab focuses on the SUMO family of small ubiquitin-related proteins. We study the covalent conjugation of SUMOs to other cellular proteins, which regulates numerous processes needed for cell growth and differentiation, and which, when defective, can lead to conditions such as cancer, neurodegenerative disease and diabetes.
  • Hsin-Chieh Yeh Lab

    Work in the Hsin-Chieh Yeh Lab focuses on clinical trials and cohort studies of diabetes, obesity and behavioral intervention, cancer and hypertension. Recent investigations have focused on novel risk factors and complications related to obesity and type 2 diabetes, particularly lung function, smoking and cancer. We recently co-led a randomized clinical trial of tailored dietary advice for consumption of dietary supplements to lower blood pressure and improve cardiovascular disease risk factors in hypertensive urban African Americans.

    Principal Investigator

    Jessica Yeh, PhD

    Department

    Medicine

  • Thomas W. Donner Lab

    The Thomas W. Donner Lab focuses on type 1 and type 2 diabetes, with an emphasis on the prevention of complications in patients with these conditions. We’re currently collaborating with Dr. Abdel Hamad to inhibit B-regulatory cell apoptosis through a novel monoclonal antibody that targets the probable apoptotic factor. We also lead a multi-center, international consortium of researchers studying ways to prevent type 1 diabetes and preserve insulin secretion in people who have been recently diagnosed with the chronic condition.

    Principal Investigator

    Tom W. Donner, MD

    Department

    Medicine

  • Todd Brown Lab

    The Todd Brown Lab focuses on metabolic, endocrine and skeletal abnormalities in HIV-infected patients, particularly as these factors relate to aging. Our studies take an epidemiologic approach to understanding the occurrence and prevalence of insulin resistance, diabetes, and anthropometric changes in HIV patients and their relationship to antiretroviral treatment.

    Principal Investigator

    Todd T. Brown, MD PhD

    Department

    Medicine

  • Rita Kalyani Lab

    Research in the Rita Kalyani Lab examines the decreased physical functioning observed in patients with diabetes as they age. Through several ongoing epidemiological cohorts, we are investigating the association of high blood glucose and high insulin levels with accelerated muscle loss, and possible contributions to the physical disability observed in diabetes. We are currently involved in clinical studies that aim to understand the underlying mechanisms for these associations and to facilitate the development of novel strategies to prevent muscle loss and disability in people with diabetes.

    Principal Investigator

    Rita Rastogi Kalyani, MD MHS

    Department

    Medicine

  • Ron Banerjee Lab

    Our research aims to expand the understanding of how hormones regulate pancreatic islets in health and disease. Currently, a major focus of the lab is to define the normal adaptations of islets, particularly insulin-producing beta-cells, to the metabolic stress of pregnancy, and to determine how defective adaptation contributes to gestational diabetes mellitus (GDM). We anticipate that elucidating physiologic mechanisms of gestational beta-cell adaptation will identify novel therapeutic strategies to expand functional beta-cell mass which would help in the treatment of all types of diabetes.